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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to  
Monurelle® and reduction of bacterial colonisation of the urinary tract by 
the inhibition of  the adhesion of P-fimbriated E.coli to uroepithelial cells  
pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Zambon B.V., submitted for authorisation of a health claim pursuant to Article 
13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the Panel on Dietetic 
Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a 
health claim related to Monurelle® and reduction of bacterial colonisation of the urinary tract by the inhibition 
of the adhesion of P-fimbriated E.coli to uroepithelial cells. The food that is the subject of the health claim, 
Monurelle®, which is a combination of 120 mg cranberry (Vaccinium macrocarpon) extract (including 36 mg 
proanthocyanidins) and 60 mg of ascorbic acid, is sufficiently characterised. The claimed effect proposed by the 
applicant is reduction of E.coli adhesion to uroepithelial cells. The Panel considers that reduction of bacterial 
colonisation of the urinary tract by inhibition of the adhesion of P-fimbriated E.coli to uroepithelial cells is a 
beneficial physiological effect. Several health claim applications on cranberry products standardised by their 
proanthocyanidin content have already been evaluated by EFSA with an unfavourable outcome. The Panel notes 
that  no  studies  from  which  conclusions  could  be  drawn  for  the  scientific  substantiation  of  the  claim  were 
provided by the applicant. The Panel concludes that a cause and effect relationship has not been established 
between the consumption of Monurelle® and reduction of bacterial colonisation of the urinary tract by inhibition 
of the adhesion of P-fimbriated E.coli to uroepithelial cells. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following an application from Zambon B.V. submitted pursuant to Article 13(5) of Regulation (EC) 
No  1924/2006  via  the  Competent  Authority  of    the  Netherlands,  the  Panel  on  Dietetic  Products, 
Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a 
health claim related to Monurelle® and reduction of bacterial colonisation of the urinary tract by 
inhibition of the adhesion of P-fimbriated E.coli to uroepithelial cells. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. 
The food that is the subject of the health claim, Monurelle®, which is a combination of 120 mg 
cranberry  (Vaccinium  macrocarpon)  extract  (including  36  mg  proanthocyanidins)  and  60  mg  of 
ascorbic acid, is sufficiently characterised. 
The claimed effect proposed by the applicant is “inhibition of the adhesion of the P-fimbriated E. coli 
bacteria to uroepithelial cells”. Upon a request by EFSA, the applicant clarified that the claimed effect 
does not refer to the reduction of urinary tract infections. Upon a request by EFSA, the applicant 
clarified that the target population is adult women. The Panel considers that reduction of bacterial 
colonisation of the urinary tract by inhibition of the adhesion of P-fimbriated E.coli to uroepithelial 
cells is a beneficial physiological effect. 
The applicant provided only one ex vivo study with the substance complying with the specification of 
the  food  which  is  the  subject  of  the  claim.  Other  studies  submitted  included  13  ex  vivo  studies 
investigating the anti-adherence activity of human urine on uropathogenic  E.coli strains following 
consumption of cranberry products other than Monurelle® product. Four ex vivo studies measuring 
antibacterial  activity  of  human  urine  following  consumption  of  cranberry  products  other  than 
Monurelle® were also submitted. The applicant also referred to nine published opinions regarding 
cranberry products and  urinary tract infections. 
The Panel notes that several health claim applications on cranberry products standardised by their 
proanthocyanidin content have already been  evaluated by EFSA. Although the in vitro anti-adherence 
effect of urine on uropathogenic  E. coli strains following consumption of cranberry products  was 
demonstrated in studies provided in these applications, such studies did not establish the validity of 
anti-adherence effects shown in vitro to predict the occurrence of a physiologically relevant bacterial 
anti-adherence effect within the urinary tract. 
No human in vivo studies from which conclusions could be drawn for the scientific substantiation of 
the claim were provided by the applicant. 
A randomized, double-blind, placebo-controlled cross-over study (Tempera et al., 2010) was designed 
to evaluate the ex vivo inhibitory activity of  urine samples from female volunteers (aged 18-65 years) 
after  one  week’s  consumption  of  Monurelle®  on  the  adhesiveness  of  two  strains  of  E.coli  to 
uroepithelial human cells. Two groups of 12 female volunteers each were enrolled, one group with 
negative  history  and  one  group  with  positive  history  of  recurrent  cystitis.  Adhesion  tests  were 
performed  using  HT1376  human  bladder  carcinoma  cells.  Urine  samples  from  participants  were 
incubated together with E.coli strains and thereafter put in contact with the uroepithelial cells. The 
adhesion index was determined by counting the average number of bacteria per cell as determined by 
examining 100 cells, with each test repeated three times.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of Monurelle® and reduction of bacterial colonisation of 
the urinary tract by inhibition of the adhesion of P-fimbriated E.coli to uroepithelial cells. 
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BACKGROUND 
Regulation  (EC)  No  1924/2006
4  harmonises the provisions that relate to nutrition and health claims ,  and 
establishes rules governing the Community authorisation of health claims made on foods.  As a rule, health 
claims are prohibited unless they comply  with the general and specific requirements of  this Regulation, are 
authorised in accordance with this Regulation, and are included in the lists of authorised claims provided for in 
Articles 13 and 14 thereof. In particular, Article 13(5) of this Regulation lays down provisions for the addition of 
claims (other than those referring to the reduction of disease risk and to children’s development and health) 
which  are  based  on  newly  developed  scientific  evidence,  or  which  include  a  request  for  the  protection  of 
proprietary data, to the Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of permitted 
claims referred to in Article 13(3) shall be submitted by the applicant to the national competent authority of a 
Member State, which will make the application and any supplementary information supplied by the applicant 
available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
  The application was received on 23/06/2012. 
  The  scope  of  the  application  was  proposed  to  fall  under  a  health  claim  based  on  newly 
developed scientific evidence. 
  On 09/08/2012, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
  On 11/09/2012, EFSA received the missing information as submitted by the applicant. 
  The scientific evaluation procedure started on 28/09/2012. 
  On 25/10/2012, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 30/10/2012 and restarted on 14/11/2012, in compliance with Article 18(3) of 
Regulation (EC) No 1924/2006. 
  On  14/11/2012,  EFSA  received  the  requested  information  (which  was  made  available  to 
EFSA in electronic format on 13/11/2012). 
  During  its  meeting  on  24/01/2013,  the  NDA  Panel,  having  evaluated  the  data  submitted, 
adopted an opinion on the scientific substantiation of a health claim related to Monurelle® and 
reduction of bacterial colonisation of the urinary tract by inhibition of the adhesion of P-
fimbriated E.coli to uroepithelial cells. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion 
on the scientific substantiation of a health claim related to Monurelle® and reduction of bacterial 
colonisation of the urinary tract by inhibition of the adhesion of P-fimbriated E.coli to uroepithelial 
cells.  
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of Monurelle®, a positive assessment of its safety, nor a decision on whether Monurelle® is, or is not, 
classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework of 
Regulation (EC) No 1924/2006. 
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. Monurelle® and reduction of bacterial colonisation of the urinary tract  
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It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. Monurelle® and reduction of bacterial colonisation of the urinary tract  
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Zambon B.V., Basicweg 14b 3821 BR Amersfoort, the Netherlands. 
Food/constituent as stated by the applicant 
According  to  the  applicant,  the  food  for  which  this  health  claim  is  made  is  Monurelle®,  a  food 
supplement constituted of 120 mg cranberry (Vaccinium macrocarpon) extracts (including 36  mg 
proanthocyanidins) and 60 mg ascorbic acid.  
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect is the inhibition of the adhesion of P-fimbriated E. coli 
bacteria to uroepithelial cells.  Without adhesion Escherichia coli cannot infect the mucosal surface of 
the urinary tract. The general anti-adhesion properties of cranberry were discovered over 20 years ago, 
challenging the original belief that the acidity of fruit was responsible for the antibacterial effect.  
Upon a request by EFSA, the applicant clarified that the claimed effect does not refer to the reduction 
of urinary tract infections, and that the target population is adult women. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wordings for the health claim: “Proanthocyanidins from 
Monurelle®  may  help  to support  defence  against  bacterial  pathogens in  the  lower  urinary  tract”; 
“Proanthocyanidins from Monurelle® cranberry product may help to reduce the P-fimbriated E. coli 
adhesion to uroepithelial cells”; “The in vitro and ex vivo studies conducted with Monurelle® or with 
urine from subjects who consumed Monurelle® show an inhibition of the adhesion of the P-fimbriated 
E. coli bacteria to uroepithelial cells”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed an intake of one tablet per day of Monurelle® supplying 36 mg/day of 
proanthocyanidins. The target population proposed is adult women. 
ASSESSMENT 
1.  Characterisation of the food/constituent 
Upon a request by EFSA, the applicant stated that the food that is the subject of the health claim is the  
Monurelle® product that  is a  combination of 120 mg cranberry (Vaccinium macrocarpon) extract 
(including 36 mg proanthocyanidins) and 60 mg of ascorbic acid. 
The proanthocyanidins (PAC) constitute a group of flavan-3-ols ranging from dimers to polymers. The 
monomeric flavan-3-ols (catechin and epicatechin) are not considered PACs. There are differences in 
the linkages (A- or B-type) between the monomeric units. The cranberry extract is standardised to 
30%  proanthocyanidins  expressed  as  procyanidin  C1  in  chromatographic  (HPLC)  analysis.  The 
product also contains ascorbic acid (vitamin C). Data on batch-to-batch variability were given. The 
stability of the product is established for six months.    
The Panel considers that the food product, Monurelle®, a combination of proanthocyanidins from 
cranberries and ascorbic acid, which is the subject of the health claim, is sufficiently characterised. 
2.  Relevance of the claimed effect to human health 
The claimed effect is “inhibition of the adhesion of P-fimbriated E. coli bacteria to uroepithelial cells”. 
Upon a request by EFSA, the applicant clarified that the claimed effect does not refer to the reduction 
of urinary tract infections, and that the target population is adult women. Monurelle® and reduction of bacterial colonisation of the urinary tract  
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Bacterial adherence to mucosal surfaces is facilitated by fimbriae, which are proteinaceous fibres on 
the bacterial cell wall (Beachey, 1981; Duguid et al., 1955). Preventing adhesion facilitates urinary 
flushing of the bacteria,  thereby preventing bacterial colonisation of the urinary tract (Foo et al., 
2000).  
The Panel considers that reduction of bacterial colonisation of the urinary tract by inhibition of the 
adhesion of P-fimbriated E.coli to uroepithelial cells is a beneficial physiological effect. 
3.  Scientific substantiation of the claimed effect 
A Medline/Pubmed database was used in literature search with the following key words: (i) Vaccinium 
macrocarpon,  cranberry,  canneberge,  (ii)  proanthocyanidins,  (iii)  vitamin  C,  ascorbic  acid,  (iv) 
Escherichia  coli,  urinary  tract  infection,  uropathogens.  In  addition,  companies  involved  with  the 
distribution of Vaccinium macrocarpon preparations were asked to provide information about both 
published and unpublished trials. A manual search of review articles was also performed. 
The applicant provided only one ex vivo study with the substance complying with the specification of 
the  food  which  is  the  subject  of  the  claim.  Other  studies  submitted  included  13  ex  vivo  studies 
investigating the anti-adherence activity of human urine following consumption of cranberry products 
other than the Monurelle® product on uropathogenic E.coli strains. Four ex vivo studies measuring 
antibacterial  activity  of  human  urine  following  the consumption  of  cranberry  products  other  than 
Monurelle® were also submitted. The applicant also referred to nine published opinions regarding 
cranberry  products  and  urinary  tract  infections  (five  opinions  of  the  AFSSA/ANSES,  one 
recommendation of the AFSSAPS, and three opinions of EFSA). 
The Panel notes that several health claim applications on cranberry products standardised by their 
PAC content have been  evaluated already by EFSA (EFSA 2009; EFSA 2011). Although the in vitro 
anti-adherence effect of urine on uropathogenic E. coli strains following consumption of cranberry 
products was demonstrated, such studies did not establish the validity of anti-adherence effects shown 
in vitro to predict the occurrence of a physiologically relevant bacterial anti-adherence effect within 
the urinary tract. 
No human in vivo studies from which conclusions could be drawn for the scientific substantiation of 
the claim were provided by the applicant. 
A  randomized,  double-blind,  placebo-controlled  cross-over  study  (Tempera  et  al.,  2010)  with  the 
product complying with the specification (as described in Section 1 above) was designed to evaluate 
the ex vivo inhibitory activity of  urine samples from female volunteers (aged 18-65 years) after one 
week consumption of Monurelle® on the adhesiveness of two strains of E.coli to uroepithelial human 
cells. Two groups of 12 female volunteers each were enrolled, one group with negative history and 
one group with positive history of recurrent cystitis. Adhesion tests were performed using HT1376 
human bladder carcinoma cells. Urine samples from participants were incubated together with E.coli 
strains, and thereafter put in contact with the uroepithelial cells. The adhesion index was determined 
by counting the average number of bacteria per cell as determined by examining 100 cells with each 
test repeated three times. The Panel considers that no evidence was provided to show that this in vitro 
study can predict the occurrence of a physiologically relevant bacterial anti-adherence effect within 
the human urinary tract.  
The  Panel  concludes  that  a  cause  and  effect  relationship  has  not  been  established  between  the 
consumption of Monurelle® and reduction of bacterial colonisation of the urinary tract by inhibition of 
the adhesion of P-fimbriated E.coli to uroepithelial cells.  
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: Monurelle® and reduction of bacterial colonisation of the urinary tract  
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  The  food  product,  Monurelle®,  which  is  the  subject  of  the  health  claim,  is  sufficiently 
characterised. 
  The claimed effect is “help to reduce the P-fimbriated E. coli adhesion to uroepithelial cells”. 
The target population as proposed by the applicant is adult women. Reduction of bacterial 
colonisation  of  the  urinary  tract  by  inhibition  of  the  adhesion  of  P-fimbriated  E.coli  to 
uroepithelial cells is a beneficial physiological effect. 
  A  cause  and  effect  relationship  has  not  been  established  between  the  consumption  of 
Monurelle® and reduction of bacterial colonisation of the urinary tract by inhibition of the 
adhesion of P-fimbriated E.coli to uroepithelial cells. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on Monurelle® pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim 
serial No: 0362_NL). July 2012. Submitted by Zambon B.V. 
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GLOSSARY AND ABBREVIATIONS 
AFSSAPS  Agence Francaise de Sécurité Sanitaire des Produits de Santé 
ANSES   Agence Nationale de Sécurité Sanitaire de l'Alimentation 
HPLC    high performance liquid chromatography 
PAC    proanthocyanidins 
UTI    urinary tract infection 
 